Lexicon Pharmaceuticals, Inc. LXRX
NASDAQ · United States · Health Technology
$1.84-0.04 (-2.13%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.
LX-9211’s novel oral, non-opioid mechanism, positive Phase II data and Phase III progress position it to address unmet neuropathic pain needs and create partnering opportunitiesDublin, Sept. 25, 2026 (GLOBE NEWSWIRE) -- "LX-9211 Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The "LX-9211 Sales Forecast and Market Size Analysis - 2034" report provides a comprehensive assessment of pilavapadin (LX-9211), Lexicon Pharmaceuticals' investigationa
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.